Epitogen IgG Lyme ELISA Kit, 44 samples

The Epitogen Lyme IgG Test is an innovative, peptide-based indirect ELISA kit to accurately detect anti-Borrelia burgdorferi IgG antibodies in human serum or plasma, indicating an immune adaptive response to B. burgdorferi and thus recent or prior Lyme disease infection. This kit offers a 9.6% higher sensitivity than the best performing commercial test without sacrificing specificity.

This cutting-edge kit employs mosaic antigens that are developed using novel EpitoPredikt™ and Epitogen® technologies.  EpitoPredikt™ is used to identify and select 120 immunodominant peptides based on 37 Borrelia antigens. To ensure high specificity, cross-reactive peptides are identified and eliminated. The selected peptides are then fused to Epitogen® constructs, creating the basis of the test. EpitoGen Technology efficiently expresses short epitopes to vastly improve antibody tests. The epitope antigen (EpitoGen) can be fused in the middle of an inert scaffold protein and displayed on the top of the scaffold, making it ideally suited for a number of antigen/antibody-based assays such as ELISA and lateral flow. 

This novel approach improves specificity by accounting for the heterogenous immune response that patients display to B. burgdorferi on a population level and maximizes the different antibodies to the diverse range of Lyme disease-causing bacteria that can be detected. Because of its dramatically enhanced performance compared to other assays on the market, the Epitogen Lyme IgG Test an excellent tool for the early detection of Lyme disease.

These kits are currently for Research Use Only.